ERC Pharma
ActiveSummary
The computed 12-month bankruptcy probability of ERC Pharma is 2.1% (moderate). The 2024 annual accounts show negative equity (-€51,962) and a net result of -€151,962. Its solvency ranks better than 20% of 15862 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
Axes
Profitability14
Solvency24
Growth-
Track record67
Bankruptcy probability, 12 months
2.1%
Moderate
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.26; short-term debt: 47% and cash: 0% of total assets), and equity is negative.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
-1.4%
Return on assets
-4.1%
Age of the figures
21 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Wholesale trade (NACE 46)
about 21% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 26-08-2025, 26 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 1 filingDeviation from the deadline
2024
26 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its 2024 accounts 26 days after the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication What held for this company on a given day: board, seat, name?Company as of a date
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, micro schema
Equity
-€51,962
Total assets
€3.7m
Net result
-€151,962
Working capital
-€1.3m
Turnover and EBIT margin not published: the micro schema does not require them.
Balance-sheet composition
Assets €3.7m
Fixed assets
€3.2m
Current assets
€459,005
Key figures and ratios
EBITDA
-€49,353
Cash flow
-€130,150
Solvency
-1.4%
Current ratio
0.26
Debt to equity
-72.19
ROA
-4.1%
Interest coverage
-0.59
Debt
€3.8m
Debt ≤ 1 year
€1.7m
Debt > 1 year
€2.0m
Annual accounts
| Line | 2024 |
|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €21,812 |
| Other operating charges640/8 | €100 |
| Gross operating margin9900 | -€49,253 |
| Operating profit (loss)9901 | -€71,165 |
| Financial income75/76B | €2,334 |
| Recurring financial income75 | €2,334 |
| Financial charges65/66B | €83,131 |
| Recurring financial charges65 | €83,131 |
| Profit (loss) for the period before taxes9903 | -€151,962 |
| Profit (loss) for the period9904 | -€151,962 |
| Profit (loss) for the period to be appropriated9905 | -€151,962 |
| Line | 2024 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €3.7m | |
| Formation expenses20 | €1,570 | |
| Fixed assets21/28 | €3.2m | |
| Tangible fixed assets22/27 | €590,104 | |
| Land and buildings22 | €590,104 | |
| Financial fixed assets28 | €2.6m | |
| Current assets29/58 | €459,005 | |
| Amounts receivable within one year40/41 | €458,970 | |
| Other amounts receivable41 | €458,970 | |
| Cash at bank and in hand54/58 | €36 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €3.7m | |
| Equity10/15 | -€51,962 | |
| Contributions10/11 | €100,000 | |
| Outside capital11 | €100,000 | |
| Other1109/19 | €100,000 | |
| Profit (loss) carried forward14 | -€151,962 | |
| Amounts payable17/49 | €3.8m | |
| Amounts payable after more than one year17 | €2.0m | |
| Financial debts170/4 | €2.0m | |
| Amounts payable within one year42/48 | €1.7m | |
| Current portion of amounts payable after more than one year42 | €198,111 | |
| Trade debts44 | €1,091 | |
| Suppliers440/4 | €1,091 | |
| Other amounts payable47/48 | €1.5m | |
| Line | 2024 |
|---|---|
| Profit (loss) for the period9904 | -€151,962 |
| + Depreciation and write-downs630 | €21,812 |
| Operating cash flow (approximation) | -€130,150 |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
26-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 26 days late
NBB filing
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Gembloux · 1 establishment unit since 2024
Ground area
794 m²
Building footprint
722 m²
Parcel 92065B0056/00V002, Wallonia. Linked by address, not a title deed.
1 establishment unit
ERC Pharma
since 20242.356.077.243
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92065B0056/00V002 | Wallonia | 794 m² | 1 · 721 m² | - |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector and region
CORIS BIOCONCEPT
BE 0459.020.430
Gembloux
VESALE PHARMACEUTICA
BE 0452.282.591
Gembloux
ABW DENTAL
BE 0839.535.988
Andenne
Added Pharma b.v.
BE 0732.660.103
Oss
ARIAM
BE 0457.586.315
Sombreffe
This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 1,903 companies in sector 46460 we hold annual accounts for 1,117. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded09-11-2023
Fiscal year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
47730Retail sale of pharmaceutical products
Contact
E-mail
mail@ercbelgium.eu
Phone
+3281728610
Scores and ratios are computed by Checked and are not a credit decision.